Lymphoma

In a session during the 2023 National Comprehensive Cancer Network Annual Conference, Deborah M. Stephens, DO, provided important updates to treatment recommendations for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and identified key factors for selecting frontline and subsequent therapies, including IGHV gene status, 17p deletion/TP53 mutation status, age, patient comorbidities, and resistance mutations. Read More ›

Columbus, OH—Intentional modifications to diet are being investigated as a strategy to reduce chronic cancer-related fatigue, according to new data published in the journal Nutrition & Cancer by researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and The Ohio State University Wexner Medical Center. Read More ›

A head-to-head phase 3 clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has found that zanubrutinib (Brukinsa), a next-generation Bruton tyrosine kinase (BTK) inhibitor, was more effective at preventing disease progression and is better tolerated than ibrutinib (Imbruvica), a first-generation BTK inhibitor that is the current standard of care for this population of patients. Read More ›

Standard pediatric chemotherapy regimens used in the treatment of children and adolescents with high-risk Hodgkin lymphoma are often associated with late effects, including second cancers, infertility, and cardiovascular disease, as well as significantly reduced overall survival (OS). Read More ›

The results from 2 phase 3 clinical trials highlighted the superiority of CAR T-cell therapies over current standard of care (SOC) when used earlier in the course of treatment for patients with large B-cell lymphoma (LBCL). Read More ›

• Calquence Receives FDA Approval for the Treatment of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
• Despite Some Positive Trends, Report Confirms Lung Cancer Remains the Deadliest Form of Cancer

Read More ›

• Teva Will Resume Production of Vincristine in Response to Shortage
• FDA Fast-Tracks Opdivo plus Yervoy Regimen for Treatment of Advanced Liver Cancer
• FDA Grants Accelerated Approval to Brukinsa for Patients with Mantle-Cell Lymphoma

Read More ›

Chronic lymphocytic leukemia (CLL) is a cancer of B-cell lymphocytes and is the most common type of leukemia in adults. More than 20,000 Americans were diagnosed with CLL in 2018. Read More ›

In 1944, Jan G. Waldenström, MD, published his observations about a series of patients who presented with anemia, hepatosplenomegaly, hyperviscosity, bleeding, lymphoplasmacytic infiltrate in the bone marrow, and a large serum protein or “macroglobulin.”¹ Today, Waldenström’s macroglobulinemia, also known as lymphoplasmacytic lymphoma, a type of non-Hodgkin lymphoma, is classified as a rare, indolent, and heterogeneous type of lymphoma of the lymphatic system. Read More ›